Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infecti...
Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial
About this item
Full title
Author / Creator
Muangnoicharoen, Sant , Wiangcharoen, Rakpong , Nanthapisal, Sira , Kamolratakul, Supitcha , Lawpoolsri, Saranath , Jongkaewwattana, Anan , Thitithanyanont, Arunee , Luvira, Viravarn , Chinwangso, Pailinrut , Thanthamnu, Narumon , Chantratita, Narisara , Lim, Jacqueline Kyungah , Anh Wartel, T , Excler, Jean-Louis , Ryser, Martin F , Leong, Chloe , Mak, Tippi K and Pitisuttithum, Punnee
Publisher
Netherlands: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Netherlands: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Highlights•A single Ad26.COV2.S booster given 45–75 or 90–240 days after 2 BBIBP-CorV doses was well tolerated. •Robust humoral and cell-mediated immune responses were measured at day 28 in both interval groups. •Humoral responses were strongest against ancestral virus, followed by delta then omicron variants. •T-cell–produced IFN-γ increased ≈10-f...
Alternative Titles
Full title
Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial
Authors, Artists and Contributors
Author / Creator
Wiangcharoen, Rakpong
Nanthapisal, Sira
Kamolratakul, Supitcha
Lawpoolsri, Saranath
Jongkaewwattana, Anan
Thitithanyanont, Arunee
Luvira, Viravarn
Chinwangso, Pailinrut
Thanthamnu, Narumon
Chantratita, Narisara
Lim, Jacqueline Kyungah
Anh Wartel, T
Excler, Jean-Louis
Ryser, Martin F
Leong, Chloe
Mak, Tippi K
Pitisuttithum, Punnee
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10267503
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10267503
Other Identifiers
ISSN
0264-410X,1873-2518
E-ISSN
1873-2518
DOI
10.1016/j.vaccine.2023.06.043
